Witness the dominance of the Diabetes Type 1 segment, North America and Europe artificial pancreas systems market capturing over 95% of the market share by 2022’s end, set to soar even higher by 2032. Expect an impressive surge of over 200 BPS, signaling unprecedented expansion.
Fueling this exponential growth are high Year-on-Year (Y-o-Y) rates, particularly in the Diabetes Type 1 segment. Anticipate a remarkable Compound Annual Growth Rate (CAGR) of 12%, propelling revenue contributions beyond US$ 567.4 million by 2032.
Meanwhile, the Diabetes Type 2 segment takes a different trajectory, with subdued Y-o-Y growth rates throughout the forecast period. Its revenue contribution is projected to increase steadily at a CAGR of 4.1%, reflecting a contrasting dynamic.
Since 2015, the Diabetes Type 1 segment has reigned supreme, a trend poised to persist, solidifying its dominance. In contrast, the Diabetes Type 2 segment, with a market attractiveness index of 0.02, remains the least attractive segment in revenue terms, foreseeably continuing its subdued performance.
Revolutionizing Healthcare: Diabetes Type 1 Leads the Charge in North America and Europe Artificial Pancreas Systems Market
In a groundbreaking development, the Diabetes Type 1 segment emerges as the undisputed leader in driving innovation and growth within the North America and Europe artificial pancreas systems market.
Forecasted to maintain its dominance throughout the assessment period, the Diabetes Type 1 disease indication segment’s influence is set to redefine healthcare standards. Originating from its commanding presence in the North America artificial pancreas systems market since 2015, this segment’s reign continues unchallenged, boasting a remarkable market attractiveness index of 2.0.
Moreover, the momentum extends seamlessly into Western and Eastern Europe, where the Diabetes Type 1 segment is poised to maintain its hegemony, presenting unparalleled opportunities for advancement and expansion.
North America and Europe artificial pancreas systems market: segmentation
By Region:
- North America
- Western Europe
- Eastern Europe
By Distribution Channel:
- Hospitals
- E-Commerce
By Disease Indication:
- Diabetes Type 1
- Diabetes Type 2
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
